Recombinant Human Granulocyte Factor should refer to Recombinant Human Granulocyte Stimulating Factor, which has the effect of elevating granulocytes. Recombinant Human Granulocyte Stimulating Factor is a kind of drug, which can be generally used for the treatment of hypogranulocytosis after radiotherapy, the prevention of granulocytopenia in radiotherapy patients, and can also be used for the treatment of leukopenia caused by congenital immunodeficiency, aplastic anemia and other diseases. Recombinant human granulocyte stimulating factor is mainly produced through the use of human genetic recombination technology of human human granulocyte stimulating factor, and the biological activity of this drug in vivo and in vitro are basically the same. Recombinant Human Granulocyte Stimulating Factor can also regulate the hematopoietic function of the granulopoietic lineage in the human bone marrow, and can also act selectively on granulocyte hematopoietic progenitor cells, and is able to effectively promote the proliferation and differentiation, and elevate granulocytes. It is contraindicated for those who have allergic reactions to this preparation or other granulocyte stimulating factor preparations, as well as those who suffer from severe hepatic, renal, cardiac or pulmonary dysfunction. It is possible to increase naïve cells in patients with myeloid leukemia who do not have an adequate reduction of naïve cells in the bone marrow and in patients with myeloid leukemia in whom naïve cells have been identified in the peripheral blood. If you need to use recombinant human granulocyte stimulating factor, it is recommended that you use it under the guidance of a doctor and follow the doctor’s instructions to regulate the use of medication, so as not to delay treatment.